Treatment for Anhedonia
For anhedonia in the context of depression, prioritize antidepressants with demonstrated anti-anhedonic properties—specifically vortioxetine, bupropion, agomelatine, or brexpiprazole—over traditional SSRIs or SNRIs, which show limited efficacy for this symptom. 1
Pharmacological Approach
First-Line Medications
The evidence strongly indicates that not all antidepressants are equally effective for anhedonia. Traditional SSRIs and SNRIs demonstrate poor efficacy specifically for anhedonic symptoms, even when they improve overall depression scores 1, 2.
Preferred agents with anti-anhedonic properties include:
- Vortioxetine - Shows promising anti-anhedonic effects 1
- Bupropion - Demonstrates specific benefit for anhedonia 1
- Agomelatine - Evidence supports anti-anhedonic properties 1
- Brexpiprazole - Effective for anhedonic symptoms 1
Important Caveat on Treatment Response
Meta-analytic evidence reveals that treatments for depression produce smaller effect sizes for anhedonia (SMD = 0.26) compared to overall depressive symptoms 2. This means anhedonia is inherently more treatment-resistant than other depressive symptoms and requires targeted intervention rather than assuming it will resolve with general antidepressant treatment.
For Treatment-Resistant Anhedonia
When first-line agents fail, consider:
Ketamine - Emerging evidence demonstrates specific anti-anhedonic properties, particularly in bipolar depression. Studies show improvement in both patient-reported and clinician-rated anhedonia measures, with particular benefit for anxiety/somatic and mood/cognition domains 3, 4. This represents one of the most promising interventions for refractory anhedonia.
Novel agents under investigation:
Context-Specific Considerations
In Major Depressive Disorder
For moderate to severe depression with prominent anhedonia, WHO guidelines recommend tricyclic antidepressants or fluoxetine 5. However, this recommendation predates newer evidence showing superior anti-anhedonic effects of agents like vortioxetine and bupropion. The more recent research should guide selection when anhedonia is the primary target 1.
Critical point: Antidepressants should not be used for mild depressive episodes 5, and anhedonia alone (without meeting criteria for a depressive episode) does not warrant antidepressant treatment 5.
In Schizophrenia-Related Anhedonia
For negative symptoms including anhedonia in schizophrenia, the 2025 INTEGRATE guidelines recommend:
- Cariprazine or aripiprazole as preferred antipsychotic switches 6
- Low-dose amisulpride (50 mg twice daily) for predominant negative symptoms when positive symptoms are controlled 6
- Consider antidepressant augmentation despite absence of diagnosed depression, though benefits may be modest 6
- Aripiprazole augmentation in patients not already on a D2 partial agonist 6
First, address any dose reduction if positive symptoms are controlled, as excessive antipsychotic dosing can worsen negative symptoms 6.
Non-Pharmacological Interventions
Psychotherapy
Behavioral activation and cognitive-behavioral therapy principles show efficacy for anhedonia 5, 1. Face-to-face delivery appears more effective than remote (telephone/video) formats 2.
Specific techniques with evidence:
- Behavioral activation - Re-engages patients with pleasurable activities 1
- Mindfulness-based strategies 1
- Savoring techniques - Enhances positive affect 1
Neuromodulation
Repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and transcutaneous auricular vagus nerve stimulation demonstrate effectiveness, particularly when targeting specific brain regions 1.
Lifestyle Interventions
Physical activity and exercise may be considered as adjunctive treatment 5, though evidence for anhedonia-specific benefits requires further study.
Treatment Duration and Monitoring
Antidepressant treatment should continue for 9-12 months after recovery 5. However, given that anhedonia often persists despite overall symptom improvement, routine assessment of anhedonia as a distinct outcome is essential 1, 2.
Long-term data suggest that maintaining hedonic improvements is feasible and correlates with better psychosocial functioning, quality of life, and sustained remission 1.
Clinical Pitfalls to Avoid
Do not assume SSRIs will adequately treat anhedonia - They show limited efficacy for this specific symptom despite improving overall depression scores 1, 2
Do not overlook anhedonia when overall depression improves - It frequently persists as residual symptomatology and predicts poor outcomes including increased suicidality, treatment resistance, and functional impairment 1, 7
Recognize anhedonia as a predictor of poor prognosis - Its presence indicates more severe episodes, greater treatment resistance, and higher suicide risk 7
Avoid excessive antipsychotic dosing in schizophrenia - This can paradoxically worsen negative symptoms including anhedonia 6